Progress in therapy doesn’t mean always feeling good. Sometimes, it means finally feeling everything. Experiencing pain in ...

Thomas, PhD, CEO and founder of Metagenomi. “We made tremendous progress toward this goal in 2024, with accomplishments including substantially advancing MGX-001, our potentially curative ...

UNICEF-supported clinics provide essential health and nutrition services for displaced families struggling to survive.

The company is actively evaluating opportunities to maximize the therapeutic potential of this program. Nimbus continues to progress drug discovery efforts across metabolic and autoimmune targets ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Nimbus plans to initiate the first clinical trial of NDI-219216 in the first half of 2025 under the leadership of Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Area Head ...

Thomas, PhD, CEO and founder of Metagenomi. “We made tremendous progress toward this goal in 2024, with accomplishments including substantially advancing MGX-001, our potentially curative development ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...